2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate
13.4.2023 20:35:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL), today announced the release of ngenea®2, the new version of its open data management and orchestration platform for data-centric applications. Leveraging Kalray’s Data Processor Unit (DPU) acceleration cards and Kalray’s pixstor™ software-defined storage solution, ngenea®2 addresses the challenges faced by a growing number of companies across all industries to be able to process, store, and manage their data faster, more efficiently, and more securely, wherever the data is located and whatever application they use.
ngenea®2 will be demonstrated at NAB 2023 by pixitmedia, Kalray’s subsidiary specialized in storage and data management solutions for the Media & Entertainment industry, in the Amazon (AWS) Innovation Zone and in the booth of its technology partner Seagate.
NEW ADVANCED FEATURES BOOSTED BY KALRAY DPU TECHNOLOGY
An increasing number of companies face challenges in their abilities to store, access, process, and control their data easily and efficiently when working within domains such as HPC, life science, media, finance, and manufacturing, to name a few. ngenea® offers a unique solution to address these challenges. It automates data management to ensure simple and efficient access to data wherever it is needed, on premises or in the cloud, and allows developers and data analysts to run complex data-intensive workflows in an easy and cost-efficient way.
ngenea®2 introduces advanced features to further address these needs. ngenea®2 consolidates data and infrastructure management into a single point of orchestrated control, enabling developers and data scientists to launch new, globally accessible data-centric workflows in seconds, across multiple on-premises, public and private cloud endpoints simultaneously and securely through each phase of their development. ngenea®2 exposes easy-to-use interfaces (“APIs”) to allow integration of third-party storage and application solutions into the ngenea namespace, providing a unified view of and instant global access to real-time data for developers. Moreover, one major evolution of ngenea®2 is its ability to leverage Kalray’s DPUs. With Kalray’s DPUs, ngenea®2 has been designed to give developers the best performance through in-storage NVMe processing and to offer AI-assisted unprecedented levels of insight into unstructured content assets to facilitate data-centric workflows.
DISPLAYING THE LATEST TECHNOLOGIES AT THE MECCA OF BROADCASTING
NAB, held from April 15-19, 2023 in Las Vegas, is one of the largest gatherings of Media & Entertainment (M&E) professionals in the world, featuring the latest technologies, services, and products in the areas of broadcasting, streaming, production, post-production, content creation, and distribution.
At the show, Kalray, through its subsidiary pixitmedia, will demonstrate multiple use cases to highlight how ngenea®2 manages and orchestrates global M&E workflows in diverse environments that include products and services from various technology partners, including AWS and Seagate, but also Adobe, Autodesk, Avid, Blackmagic, and Projective.
DEMONSTRATING AN END-TO-END CLOUD WORKFLOW AT AWS INNOVATION ZONE
At its kiosk in the Amazon Web Services (AWS) Create Innovation Zone (North Hall N2562H), pixitmedia will display a mixed editorial environment in AWS, mirroring a solution that it has in production with a Media & Entertainment Distribution arm of a major motion picture studio.
The demonstration will showcase how Kalray’s pixstor™ and ngenea®2 bring new levels of coherence and efficiency to media production, while improving security, controlling costs, and boosting collaboration. This solution includes an Amazon Elastic Compute Cloud (EC2) workstation in a pixstor™ cloud, with Projective’s Strawberry providing project containerization of a shared storage environment, enabling Adobe, Avid, and Blackmagic DaVinci Resolve participation in the workflow – all using the same core assets.
DEMONSTRATING AUTOMATED MOVEMENT OF MEDIA WITH SEAGATE AND AUTODESK
Also, technology partner Seagate is hosting pixitmedia to display a joint hyperconverged solution with three high-end workstations running Autodesk Flame, Flame Assist, and Blackmagic DaVinci Resolve. The demonstrated solution provides high-performance finishing suites, leveraging high-speed, native access to media data on pixstor™, boosted by Kalray hardware DPU accelerator cards and with ngenea®2 automating the movement of media between a customer NAS, Avid NEXIS, and Tier0 storage.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric markets, from edge to cloud.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005705/en/
Contact information
INVESTOR CONTACTS
E
ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
S
ylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
